The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease

Atherosclerosis

Volumn 227, Issue 1, 2013, Pages 106-111

  Peng, Yong ^a   Chen, Mao ^a   Liu, Xiao jing ^a   Liu, Wei ^a   Li, Qiao ^a   Chai, Hua ^a   Ren, Xin ^a   Wang, Xue qin ^a   Zhao, Zhen gang ^a   Zhang, Chen ^a   Luo, Xiao lin ^a   Huang, De jia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Coronary artery disease; CYP2C19; Polymorphism; Prognosis

Indexed keywords

CYTOCHROME P450 2C19;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEART DEATH; HEART INFARCTION; HETEROZYGOTE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PRODRUGS; PROGNOSIS; TICLOPIDINE;

EID: 84873424359     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.12.028     Document Type: Article

References (17)

1. Gasparyan A.Y., Watson T., Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008, 51:1829-1843.
2. Shanker J., Gasparyan A.Y., Kitas G.D., Kakkar V.V. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms. Curr Vasc Pharmacol 2011, 9:479-489.
3. Kazui M., Nishiya Y., Ishizuka T., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010, 38:92-99.
4. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
5. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994, 269:15419-15422.
6. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
7. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
8. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
9. Sibbing D., Stegherr J., Latz W., et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009, 30:916-922.
10. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148-304.
11. Antman E.M., Hand M., Armstrong P.W., et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329.
12. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008, 117:261-295.
13. Yin O.Q., Tomlinson B., Chow A.H., Waye M.M., Chow M.S. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 2004, 44:582-589.
14. Mega J.L., Simon T., Collet J.P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304:1821-1830.
15. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
16. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
17. Stone G.W., Ellis S.G., Cox D.A., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109:1942-1947.